Tomás Herraiz Tomico

• Herraiz, T.; Peña, A.; Salgado, A. Identification, formation, and occurrence of perlolyrine: A β-Carboline alkaloid with a furan moiety in foods. J. Agric. Food Chem. 71(36),13451–61 (2023).

https://doi.org/10.1021/acs.jafc.3c03612

• Herraiz T. β-Carboline alkaloids in soy sauce and inhibition of monoamine oxidase (MAO). Molecules. 28(6), 2723 (2023).

https://doi.org/10.3390/molecules28062723

• Herraiz, T.; Peña, A.; Mateo, H.; Herraiz, M.; Salgado, A. Formation, characterization, and occurrence of β-carboline alkaloids derived from α-dicarbonyl compounds and L-tryptophan. J. Agric. Food Chem. 70(29), 9143–53 (2022).

https://doi.org/10.1021/acs.jafc.2c03187

• Herraiz, T; Vera, F. Occurrence, formation from D-fructose and 3-deoxyglucosone, and activity of the carbohydrate-derived β-carbolines in foods. J. Agric. Food Chem.69(23), 6650–64 (2021).

https://doi.org/10.1021/acs.jafc.1c02281

• Herraiz, T.; Guillen, H. ; González-Peña, D. ; Arán, V.J. Antimalarial quinoline drugs inhibit beta-hematin and increase free hemin catalyzing peroxidative reactions and inhibition of cysteine proteases. Scientific Reports 9, 15398 (2019).

https://doi.org/10.1038/s41598-019-51604-z

• Manzano, J.I.; Cueto-Diaz, E.J.; Olias-Molero, A.I.; Perea, A.; Herraiz, T.; Torrado, J.J. ; Alunda, J.M.; Gamarro, F.; Dardonville, C. Discovery and pharmacological studies of 4-hydroxyphenyl-derived phosphonium salts active in a mouse model of visceral Leishmaniasis. J. Med.Chem 62, 10664-10675 (2019).

https://doi.org/10.1021/acs.jmedchem.9b00998

• Desarrollo de nuevos fármacos antiparasitarios dirigidos a dúplex y cuádruplex de ADN (DNA-Q4cure).
  Referencia: PID2022-136438OB-I00.
  IP y co-IP: C. Dardonville (IQM-CSIC); A. Gomez-Barrio, UCM
  Duración: 1/09/2023 hasta 31/08/2027.
  Entidad financiadora: AEI-Cofinanciado UE.
• Estudios de seguridad e in vivo de una nueva entidad química para el tratamiento de la leishmaniasis veterinaria (VetLesihCure).
  Referencia: PDC2022-133269-I00.
  IP y co-IP: C. Dardonville (IQM-CSIC).
  Duración: 1/12/2022 hasta 30/11/2024.
  Entidad financiadora: AEI-UE-Next Generation.
• Nuevas estrategias terapéuticas para el tratamiento de transtornos degenerativos basados en el sistema endocanabinoide.
  Referencia: PID2021-127833OB-I00
  Duración: 1/08/2022 hasta 31-08-2025.
  IP y co-IP: N. Jagerovic (IQM-CSIC); A. Castro Morera, IQM-CSIC.
  Entidad financiadora: AEI-Cofinanciado UE.